CM
GALT icon

Caption Management’s Galectin Therapeutics GALT Stock Holding History

Caption Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$112K Buy
+40,000
New +$122K ﹤0.01% 1389
2025
Q1 		– Sell
-155,000
Closed -$200K – 1698
2024
Q4 		$200K Hold
155,000
– – ﹤0.01% 1276
2024
Q3 		$426K Buy
+155,000
New +$381K 0.01% 953

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Caption Management's GALT Position: Q1 2025 in Review

Caption Management sold out of Galectin Therapeutics (GALT) in Q1 2025, closing a stake of 5,475 shares — an estimated $7.06K sold.

Caption Management first reported a position in GALT in Q4 2024 and held it in 1 quarter. The position peaked at $7.06K in Q4 2024. 93 funds tracked by Wall St. Rank hold GALT as of Q1 2025.

  • Caption Management reported no remaining Galectin Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Caption Management sold 5,475 Galectin Therapeutics shares in Q1 2025, an estimated $7.06K.
  • Caption Management first reported a position in Galectin Therapeutics in Q4 2024 and held it in 1 quarter.
  • Caption Management's Galectin Therapeutics position peaked at $7.06K in Q4 2024.
  • 93 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.